Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Receivables - Net: 2021-2024

Historic Receivables - Net for Tg Therapeutics (TGTX) over the last 3 years, with Dec 2024 value amounting to $129.2 million.

  • Tg Therapeutics' Receivables - Net rose 129.32% to $265.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $265.4 million, marking a year-over-year increase of 129.32%. This contributed to the annual value of $129.2 million for FY2024, which is 152.84% up from last year.
  • As of FY2024, Tg Therapeutics' Receivables - Net stood at $129.2 million, which was up 152.84% from $51.1 million recorded in FY2023.
  • In the past 5 years, Tg Therapeutics' Receivables - Net ranged from a high of $129.2 million in FY2024 and a low of $1.4 million during FY2021.
  • Moreover, its 2-year median value for Receivables - Net was $90.1 million (2023), whereas its average is $90.1 million.
  • Data for Tg Therapeutics' Receivables - Net shows a peak YoY soared of 152.84% (in 2024) over the last 5 years.
  • Over the past 3 years, Tg Therapeutics' Receivables - Net (Yearly) stood at $1.4 million in 2021, then reached $51.1 million in 2023, then skyrocketed by 152.84% to $129.2 million in 2024.